Discovery of 2-Hydroxy-<i>N</i>,<i>N</i>-dimethyl-3-{2-[[(<i>R</i>)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist
Michael P. Dwyer, Arthur G. Taveras, Lynne Ozgur, Cynthia Aki, Laura L. Rokosz, Rosemary Mayer-Ezel, Tara M. Stauffer, Carol Terminelli, Waldemar Gonsiorek, Jianhua Chao, Diane Rindgen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jianping Chao, Viyyoor Girijavallabhan, J. Robert Merritt, Richard Bond, James Fossetta(Bloomfield College), Younong Yu, Wei Wang(Capital Medical University), Ge Li(Anhui Medical University), Hong Bian, Bernd Kaiser, Daniel Lundell, John J. Baldwin(United States Pharmacopeial Convention), James Jakway, Purakkattle Biju, Xuedong Fan(Jiangnan University), R. William Hipkin, Jay S. Fine(Boehringer Ingelheim (United States))
Cited by 116
Related Papers
Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation
|Journal of Biological Chemistry|2004|716
Selective small-molecule inhibition of an RNA structural element
|Nature|2015|419
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
|Drug Resistance Updates|2022|257
Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib
|Journal for ImmunoTherapy of Cancer|2020|153